Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12158829 | 0.70 | LMNA (0.44) | HSD11B1USP14 | |
| SCHEMBL20113373 | 0.69 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL2708301 | 0.69 | CHRM2 (0.61) | HSD11B1 | |
| SCHEMBL6997536 | 0.67 | MAPK1 (0.38) | — | |
| SCHEMBL4487545 | 0.65 | DRD2 (0.47) | HSD11B1 | |
| SCHEMBL4466683 | 0.65 | DRD2 (0.47) | HSD11B1 | |
| SCHEMBL12108434 | 0.65 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL4484205 | 0.65 | DRD2 (0.47) | HSD11B1 | |
| SCHEMBL22624062 | 0.63 | KDM4E (0.35) | HSD11B1 | |
| SCHEMBL23245337 | 0.62 | HSD11B1 (0.44) | HSD11B1USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | HSD11B1 3834/4885USP14 4100/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | HSD11B1 3834/4885USP14 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.